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Abstract
Background: Metastatic pancreatic adenocarcinoma has a short median overall survival (OS) of
5–6 months. However, a subgroup of patients survives more than 1 year. We analyzed the survival
outcomes of this subgroup and evaluated clinical and pathological factors that might affect survival
durations.
Methods: We identified 20 patients with metastatic or recurrent pancreatic adenocarcinoma who
received single-agent gemcitabine and had an OS longer than 1 year. Baseline data available after
the diagnosis of metastatic or recurrent disease was categorized as: 1) clinical/demographic data (age,
gender, ECOG PS, number and location of metastatic sites); 2) Laboratory data (Hematocrit,
hemoglobin, glucose, LDH, renal and liver function and CA19-9); 3) Pathologic data (margins, nodal
status and grade); 4) Outcomes data (OS, Time to Treatment Failure (TTF), and 2 year-OS). The
lowest CA19-9 levels during treatment with gemcitabine were also recorded. We performed a
univariate analysis with OS as the outcome variable.
Results: Baseline logarithm of CA19-9 and total bilirubin had a significant impact on OS (HR = 1.32
and 1.31, respectively). Median OS and TTF on gemcitabine were 26.9 (95% CI = 18 to 32) and 11.5
(95% CI = 9.0 to 14.3) months, respectively. Two-year OS was 56.4%, with 7 patients alive at the
time of analysis.
Conclusion: A subgroup of patients with metastatic pancreatic cancer has prolonged survival after
treatment with gemcitabine. Only bilirubin and CA 19-9 levels were predictive of longer survival in
this population. Further analysis of potential prognostic and predictive markers of response to
treatment and survival are needed.
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Background
Pancreatic cancer is the fourth leading cause of death in
men and fifth in women in the United States [1]. An esti-
mated 37,680 new patients and approximately 34,290
deaths are expected to occur from this disease in 2008. It
has a poor prognosis with less than 5% of all patients alive
5 years after diagnosis [2]. Surgical resection remains the
only curative approach. Unfortunately, by the time of
diagnosis, only 15% of patients have resectable tumors.
Within this group, the 5-year survival is 20–25% [2,3].
The vast majority of patients present with locally
advanced or metastatic disease. For the metastatic group,
the overall survival (OS) ranges between only 3 to 6
months [4-6]. At present, palliative chemotherapy is con-
sidered the treatment of choice for patients with meta-
static disease and good performance status. Prior to 1996,
standard chemotherapy usually consisted of 5-fluorour-
acil (5-FU) based regimens, with small impact on OS [7-
10].
Gemcitabine (difluorodeoxycytidine; dFdCA) is a nucleo-
side analog with broad antitumor activity. When com-
pared to 5-FU in a randomized phase III trial, there was a
modest improvement in OS (5.6 vs. 4.4 months) as well
as a higher rate of clinical benefit (24% to 5%) favoring
gemcitabine [11]. Consequently, gemcitabine has become
the standard of care for metastatic or recurrent adenocar-
cinoma of the pancreas. Studies over the past 10 years
have tried to improve on single agent, standard 30-minute
gemcitabine therapy. A randomized phase II trial between
standard 30-minute infusion of gemcitabine against a
fixed dose-rate infusion of 10/mg/m2/min of the same
drug revealed a significant benefit in 1 and 2-year OS for
the prolonged infusion rate [12]. Several trials have evalu-
ated whether there is any benefit for gemcitabine-based
combinations, including molecular targeted agents, over
gemcitabine alone. Although several of these have shown
a higher response rate favoring the combined regimens, a
clear benefit in OS has yet to be shown [13-16]. Despite
the benefit of gemcitabine, most patients with advanced
disease still do poorly, with a median Time-to-Tumor Pro-
gression (TTP) between 2 to 3 months and median OS of
5 to 6 months. The one-year OS varies from 2 to 32% in
the most recently published series [11,13,17]. Such a
broad variation can be partially explained by the fact that
some of these studies have also included patients with
locally advanced disease, with median survival ranging
from 9 to 12 months. However, those results may also
suggest that a subgroup of patients with metastatic and/or
recurrent disease may experience prolonged survival when
treated with gemcitabine. Whether these patients bene-
fited from treatment or represented a selected population
with favorable prognosis is unknown.
The identification of potential predictors of long-term sur-
vival in patients with metastatic pancreatic cancer can
help physicians in the decision-making process for indi-
vidual patients. Once identified, these factors could also
be useful in designing future clinical trials. In an attempt
to assess the clinical and pathological predictors of pro-
longed survival, we performed a systematic review and
outcome analyses of patients with adenocarcinoma of the
pancreas who survived more than one year from the diag-
nosis of metastatic or recurrent disease and received gem-
citabine.
Methods
This systematic review received the approval of the local
Institutional Review Board. All information regarding the
patients included in the study remained confidential dur-
ing and after data collection.
We searched for patients with metastatic or recurrent pan-
creatic adenocarcinoma diagnosed from March 1996 to
July 2002 who were treated with gemcitabine in the out-
patient clinic at Massachusetts General Hospital Cancer
Center. Patients and chemotherapy regimens were que-
ried through the institutional tumor registry database. We
selected the following inclusion criteria: histopathological
diagnosis of pancreatic adenocarcinoma based on the
reports and confirmed on an independent review of path-
ological specimens; metastatic disease at presentation or
recurrent disease after surgery or chemoradiation for local
or locally advanced disease, respectively; a survival longer
than 12 months from the initial diagnosis of metastatic or
recurrent disease; palliative treatment with gemcitabine.
Patients could have received additional chemotherapy or
experimental therapy after failure or intolerance to gem-
citabine. We adopted the following exclusion criteria: his-
topathological type other than adenocarcinoma,
periampullary cancers, other active cancers, brain metas-
tasis as the single metastatic site, patients not treated with
gemcitabine, or survival shorter than 12 months from the
initial diagnosis of metastatic disease or from documenta-
tion of recurrence. Patients did not need to have measur-
able disease to be enrolled.
A systematic review of the charts was performed. We
searched for baseline information present at the time of
the diagnosis of metastatic or recurrent disease. The only
data evaluated during gemcitabine treatment was the
serum CA19-9 level. When patients underwent surgery as
the initial treatment before recurrence, the pathological
report and material of the procedure were also reviewed.
The data were grouped and analyzed in four major catego-
ries:Journal of Hematology & Oncology 2009, 2:13 http://www.jhoonline.org/content/2/1/13
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1) Demographic/clinical data
Patients' age, gender, ECOG PS, number of metastatic or
recurrent sites, and location of metastatic/recurrent dis-
ease.
2) Laboratorial data
Baseline blood tests such as hematocrit (hct), hemoglobin
(hgb), renal and hepatic functions, LDH, glucose, CA19-
9, and lowest CA19-9 value during treatment with gemcit-
abine or combinations.
3) Pathological data
In all cases, the available diagnostic material was reviewed
to confirm that all tumors were adenocarcinoma. The
degree of differentiation (well, moderate, and poor) was
recorded. For the resected cases, the size of the tumor,
marginal status and number of positive nodes were also
collated.
4) Outcomes data
We determined the median OS, 2-year OS, and median
time to treatment failure (TTF) on gemcitabine as well as
the median number of chemotherapeutic/investigational
regimens. Survival is shown as medians with 95% confi-
dence intervals (95% CI). Response rates according to
serial CT scans and CA 19-9 levels were determined. We
analyzed CT scan responses based on modified WHO cri-
teria to define a response [18]. CA 19-9 responses were
defined as a ≥ 50% drop from the baseline level seen in
any measurement during gemcitabine treatment. For both
CT scan and CA 19-9 methods, we compared the OS of
responders vs. non-responders by non-paired student's t-
test.
A univariate regression analysis was undertaken to exam-
ine any potential factors that might impact on OS. As we
did not detect more than two significant factors, we did
not proceed with a multivariate analysis. The Cox propor-
tional hazard model was used for all variables [19]. OS
curves were obtained through the Kaplan-Meyer method
[20]. Alive subjects were censored by the last medical visit.
Death dates were available in the charts or through the
web site page http://www.rootsweb.com.
Results
From March 1996 to September 2002, we identified 435
patients with adenocarcinoma of the pancreas with either
distant metastasis at diagnosis or recurrent cancer after
surgical resection or progressive disease after chemoradia-
tion for locally advanced disease. Of these, 22 patients
had an OS longer than 12 months. Two patients were
excluded because one was diagnosed with a periampul-
lary tumor and the other one had a histological diagnosis
of mucinous cystadenocarcinoma. Therefore, 20 patients
were included in the final analysis.
All patients received gemcitabine given as single-agent.
Baseline characteristics were defined as those measured at
the time metastatic or recurrent disease was first docu-
mented. In the case of CA19-9 levels, we analyzed both
the baseline and lowest values during gemcitabine treat-
ment.
Table 1: Clinical characteristics (n = 20)
Values HR p value
Median age (Yr) 59 (38 – 72) 1.04 0.16
Gender
M 65% 0.89 0.85
F 35%
ECOG PS (%) 1.04 0.92
03 0
16 0
21 0
3 & 4 0
N° of Sites 0.80 0.74
1 75%
2 25%
>2 0%
Initial Sites 0.99 0.99
liver 15%
lung 10%
peritoneal 20%
local 25%
nodal 0%
bone 5%
combinations 25%
Median age was determined at diagnosis of metastatic disease or at 
documentation of recurrence. M = male; F = female; ECOG PS 
Performance Status according to Eastern Cooperative Oncology 
Group; NO of Sites = number of metastatic sites at diagnosis of 
metastatic disease or recurrence; Initial Sites = Proportion of initial 
metastatic/recurrent sites according to the involved organ. HR = 
Hazard ratio for Overall Survival after univariate analysis. P value = 
level of significance.Journal of Hematology & Oncology 2009, 2:13 http://www.jhoonline.org/content/2/1/13
Page 4 of 10
(page number not for citation purposes)
1) Demographic/clinical Data
Demographic and clinical data are shown in Table 1.
Median age at baseline was 59 years. Sixty-five percent of
patients were males and 35% females with a male:female
ratio of 1.85:1.0. The patients had a baseline ECOG PS of
0, 1 or 2 in 30, 60 and 10% of the cases, respectively. As
expected, none of the individuals had a baseline PS of 3 or
4. Interestingly, of the two patients with PS 2 at baseline,
one has shown an OS of 29.8 months and the other is still
alive at 13 months of follow-up, although he has had dis-
ease progression on gemcitabine. Seventy-five percent of
the individuals had only one metastatic or recurrent site at
baseline, while the remaining 25% presented with 2 sites.
None of the patients presented with more than 2 meta-
static or recurrent sites.
The initial sites of metastasis or recurrence were consid-
ered individually for subjects who had only one site.
Those with 2 sites were grouped together under the desig-
nation of "combination". Among the patients with single
site of metastasis or recurrence, 25% (n = 5) presented
with local recurrences or progression, 20% (n = 4) with
peritoneal carcinomatosis, 15% (n = 3) with liver metas-
tasis, 10% (n = 2) with lung metastasis and 5% (n = 1)
with bone metastasis only. Of the 5 patients with more
than one metastatic site, 4 had a nodal recurrence together
with another site: 2 with local recurrences, 1 with liver and
1 with lung metastasis. Only one patient had a combina-
tion of liver and peritoneal metastases.
2) Laboratory data
A summary of the tests analyzed is shown in Table 2. Most
patients had normal hepatic and renal function. The
median hematocrit level of 37.8% was slightly below the
normal range. Several individuals showed increased levels
of transaminases at baseline, but none exceeded 2.4 and
2.2 times the upper normal limits for SGOT and SGPT,
respectively. Alkaline Phosphatase (Alk. Ph.) varied from
58 to 434 U/L, with a median value of 111.5 U/L. Ten
patients (50%) demonstrated elevated levels (118 to 434
U/L) at baseline. Total bilirubin levels ranged from 0.2 to
14.6 mg/dL with a median value of 0.65 mg/dL. Five sub-
jects (25%) had elevated bilirubin levels at baseline, rang-
ing from 1.4 to 14.6 mg/dL. Two patients with bilirubin
values of 1.7 and 5.0 mg/dL, respectively, were not treated
with a biliary drainage procedure at baseline. The other 3
patients had their biliary tree decompressed surgically (1
patient) or by stent placement (2 patients). The time inter-
val from the biliary drainage procedure to baseline
bilirubin assessment was 3 weeks in 2 cases and 4 weeks
in one case. Of note, the patient with the baseline
bilirubin of 14.6 mg/dL had a successful stent placed 3
weeks earlier, when his bilirubin levels measured 21.9
mg/dL. None of the individuals presented with severe
anemia at baseline. This is highlighted by the lowest hct
and hgb levels of 30.7% and 10.4 g/dl, respectively. Serum
glucose levels were in the upper normal limit or slightly
elevated in all but one patient with diabetes mellitus who
had baseline glucose level of 247 mg/dL. The median
value for LDH was also in the normal range, although it
was increased in 6 individuals, from 214 to 1116 U/L.
Tumor marker CA19-9 demonstrated a broad variation in
the baseline values (from 11.0 to 38,000 U/L). As it
showed an exponential distribution, we also expressed the
values as the logarithm of CA19-9. The two individuals
with the highest CA19-9 values, 25,580 and 38,000, had
an OS of 12.0 and 21.6 months, respectively. The former
was alive at the time of this analysis.
3) Histopathologic data
Table 3 summarizes the histopathologic characteristics.
Six patients had undergone Whipple surgery, 6 had been
diagnosed by fine needle aspiration (FNA) and 8 by biop-
sies. In all but 2 cases (2 biopsies), the pathologic material
could be reviewed. A diagnosis of adenocarcinoma was
confirmed in all cases. In the 2 cases for which we could
not review the tissue, a diagnosis of adenocarcinoma had
been confirmed on site before the material was returned
to the referring institution.
Among the 6 resected cases, the size of the tumor was
available in 5. Only one case measured less than 3 cm (2.5
cm) while the other 4 had a median size of 4.3 cm (range:
3.3 to 6.5 cm). Pathological margins and nodal status
were assessed for the 6 surgical procedures. Of these, sta-
tus of the resected margins was reported as negative in two
cases (34%) and positive in four cases (66%). Five of the
6 resected patients had metastatic lymph nodes. The
number of positive lymph nodes ranged from 1 to 7, with
a median of 4. Excluding the cytologic material, the degree
of differentiation was evaluated in 12 patients. One case
(8%) showed a well-differentiated tumor, as opposed to
five cases (42%) of moderately differentiated and 6 cases
(50%) of poorly differentiated tumors. The subject with
the well-differentiated tumor had a survival of 57.9
months, while subjects with poorly differentiated tumors
showed a survival range from 12.4 to 24 months. An
example of the cytology sample from FNA and a pathol-
ogy specimen from Whipple surgery were shown in Fig-
ures 1 and 2, demonstrating the diagnosis of
adenocarcinoma.
4) Outcomes data
Table 4 summarizes the survival data. The median OS for
all patients was 26.9 months (95% CI = 18 – 32 months)
and the 2-year OS rate was 56.4%. Two patients had a pro-
longed OS of 57.9 and 90.9 months, respectively, and the
last one was alive at the time of the present report. The
Kaplan-Meier curve for OS is shown in Figure 3. AllJournal of Hematology & Oncology 2009, 2:13 http://www.jhoonline.org/content/2/1/13
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Table 2: Laboratory values
Tests Reference Median Range HR p value
HCT (%) 41–53 37.80 30.70 – 44.6 1.03 0.73
Hgb (g/dL) 13.5–17.5 13.20 10.40 – 15.5 1.14 0.59
Bilt (mg/dL) 0–1 0.65 0.20 – 14.6 1.31 0.02*
SGOT (mg/dL) 10–40 37.50 17 – 97 0.99 0.79
SGPT (mg/dL) 10–55 28.50 12 – 121 0.98 0.21
AP (U/L) 45–115 111.50 58 – 434 1 0.93
GLU (mg/dL) 70–110 114 69 – 247 0.99 0.88
BUN (mg/dL) 8–25 13.50 8 – 25 0.96 0.51
Cr (mg/dL) 0.60–1.50 0.80 0.50 – 1.90 0.49 0.42
LDH (U/L) 110–210 196.50 69 – 1116 0.99 0.07
CA19-9 (U/mL) 37 360 11 – 38000 1 0.28
log CA19-9 (U/mL) - 2.55 1.04 – 4.57 1.32 0.04*
log CA19-9 dif (U/mL) - 5.81 1.38 – 10.50 1.15 0.34
HCT = hematocrit; Hgb = hemoglobin; Bilt = total bilirubin; SGOT = aspartate transaminase; SGPT = alanine transaminase; AP = Alkaline 
Phosphatase; GLU = glucose; BUN = Blood Urea Nitrogen; Cr = creatinine; LDH = Lactic dehydrogenase; CA19-9 = tumor marker; log CA19-9 = 
logarithm of CA19-9; log CA19-9 dif = difference between the logarithm of pre- and post-therapy CA19-9 levels. HR = Hazard ratio for Overall 
Survival after univariate analysis. P value = level of significance.Journal of Hematology & Oncology 2009, 2:13 http://www.jhoonline.org/content/2/1/13
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patients were initially treated with single-agent gemcitab-
ine.
The median TTF on gemcitabine was 11.5 months (95%
CI = 9.0 – 14.3). These results contrast substantially with
the usual TTF of 2 to 3 months on gemcitabine for non-
selected populations with metastatic pancreatic cancer.
However, TTF on gemcitabine varied significantly among
these patients ranging from 5.7 to 50.8 months. Interest-
ingly, the subject with the shortest TTF (5.7 months) had
the longest OS (90.9 months). On the other hand, the
individual who survived for 57.9 months spent 50.8
months on gemcitabine. Together, these results suggest
that, even among patients with prolonged survival, the
presumed benefit from gemcitabine can differ signifi-
cantly.
All 20 patients had serial CT scans available for response
analysis. Five patients (25%) had an objective radiological
response. Their median OS was 24.0 months, compared
to an OS of 18.8 months for non-responders (p = 0.66).
Of 19 patients with CA 19-9 levels available, 12 (63%)
showed a tumor marker response. As shown in Table 5,
the median OS of responders was 20.5 months, compared
to a median OS of 26.9 months for non-responders (p =
0.45.). Of the 5 patients with a radiological response, 4
(80%) also had a tumor marker response. Five patients
were additionally followed by PET scans. All of them
showed some reduction of tumor uptake of 18Fluoro-
Table 3: Pathologic characteristics
Features Values HR p value
Adenocarcinoma (n = 20) 100% NA NA
Grade (n = 12) 1.22 0.78
well 8%
mod 42%
Poorly 50%
Margins status (n = 6) NA NA
negative 34%
positive 66%
median nodes (n = 6) 4 (1 – 7) NA NA
Margins and nodal status were reported only for the cases initially 
treated with surgery (Whipple's procedure). Grade status was 
reported in 12 cases. Description: n = number of subjects; well = well 
differentiated; mod = moderately differentiated; poorly = poorly 
differentiated. HR = Hazard ratio for Overall Survival after univariate 
analysis. P value = level of significance.
Cytology from one FNA showed a moderately differentiated  ductal adenocarcinoma Figure 1
Cytology from one FNA showed a moderately differ-
entiated ductal adenocarcinoma. It was characterized by 
a cohesive group of malignant cells showing nuclear crowding 
and overlapping. Minimal nuclear irregularity and prominent 
nucleoli can be seen (Papanicolaou 40× per High Power 
Field).
Pathology from one Whipple specimen showed ductal aden- ocarcinoma, moderately differentiated Figure 2
Pathology from one Whipple specimen showed duc-
tal adenocarcinoma, moderately differentiated. Irreg-
ularly shaped malignant glands infiltrated the desmoplastic 
stroma. Marked nuclear atypia was observed (Hematoxylin 
and Eosin 40× per High Power Field).Journal of Hematology & Oncology 2009, 2:13 http://www.jhoonline.org/content/2/1/13
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deoxy-glucose (FDG), and two patients had a complete
normalization of PET scans. None of the patients with a
PET response obtained a CT scan response. All of the
patients with PET responses showed a CA 19-9 response.
The number of systemic treatment regimens ranged from
1 to 6, with a median number of 1. If we consider only the
patients who received more than one chemotherapy line
(50%), the median number of treatments was 3. There
was no significant difference in the overall survival of
patients treated with one line of chemotherapy compared
with patients treated with 2 or more lines (median OS 18
vs. 24 months, HR = 0.84; p = 0.29).
Gemcitabine was well tolerated in this population. How-
ever, we observed two cases of hemolytic uremic syn-
drome (HUS) (10%). They occurred 6 and 8 months after
the onset of gemcitabine treatment, respectively. The first
patient survived for 14 months after the diagnosis of HUS,
and died of disease progression with an overall survival
time of 26.9 months. The second patient is still alive 15
months after the diagnosis of HUS. His renal function has
significantly improved and he is left with a slight residual
decrease in his renal function.
5) Univariate Analysis
Using the Cox proportional hazard model, we tested all
variables for significant impact on OS (Table 2). Only log
Survival curve according to Kaplan-Meier method Figure 3
Survival curve according to Kaplan-Meier method. Individuals alive at the time of the study were censored and repre-
sented as dashes on the curve.Journal of Hematology & Oncology 2009, 2:13 http://www.jhoonline.org/content/2/1/13
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CA19-9 at baseline and total bilirubin (bilt) had a nega-
tive impact on OS (HR = 1.32; p = 0.044 and HR = 1.31;
p = 0.021, respectively). There was no statistical signifi-
cant association between Log CA19-9 response during
gemcitabine and OS (HR = 1.15; p = 0.34).
Potential prognostic factors such as ECOG-PS, positive
margins, histologic grade, and nodal status of the initial
surgical specimen as well as number of initial metastatic
sites did not demonstrate a significant impact on OS
[21,22]. The only patient with a well-differentiated aden-
ocarcinoma had a prolonged survival of 57.9 months. The
median OS of 6 patients with well and moderately differ-
entiated tumors was 27.4 months, compared to a median
OS of 18.9 months of 6 patients with poorly differentiated
tumors (p = 0.106, using a non-paired student's t-test).
Discussion
A subgroup of patients with metastatic or recurrent pan-
creatic cancer have outcomes that are significantly better
than the average patient population. This study sample
represents only approximately 5% of patients treated with
palliative gemcitabine at this institution. This proportion
of long-term survivors is relatively low when compared
with most randomized clinical trials of gemcitabine [11-
17]. Potential explanations for this low 1-year survival
rate include incomplete ascertainment of long-term survi-
vors, an overall worse prognosis of patients referred for
treatment at our institution (referral bias), and the selec-
tion of patients with better performance status in clinical
trials (selection bias). It is also possible that some patients
from our initial population (n = 435) never received gem-
citabine due to rapid tumor progression.
The median OS and TTF on gemcitabine were 26.9 and
11.5 months, respectively, while most of the randomized
trials with single agent or gemcitabine-based combina-
tions report OS and TTP between 3.8 to 6.7 months and
2.2 to 3.5 months, respectively [13-16]. The striking dif-
ferences in survival outcomes between this group of
patients and patients on randomized trials suggest two
possible explanations: 1) selected patients receive signifi-
cant benefit from gemcitabine or 2) this selected popula-
tion has a better prognosis independent of treatment
modality. Clearly, some combination of these might also
be true. Given the retrospective nature of this analysis, no
firm conclusion differentiating these two possibilities can
be made. However, several findings suggest that treatment
with gemcitabine accounts, at least in part, for the pro-
longed survival of these patients. The 25% response-rate
to gemcitabine seen in this study is considerably higher
than the 5–10% described in the literature [11-13,15].
Although the differences in OS between CT scan respond-
ers and non-responders (24 and 18.8 months, respec-
tively) did not reach statistical significance, there was a
trend towards longer survival in responders. The TTF on
gemcitabine for the entire group of patients was 11.5
months, significantly longer than that in unselected
patients. However, this retrospective study does not allow
us to attribute the observed long-term outcomes to either
increased gemcitabine responsiveness in selected patients
or the presence of prognostic factors associated with pro-
longed survival.
There were no clinical characteristics that predicted long-
term survival within this group. Interestingly, commonly
considered prognostic factors in metastatic pancreatic
cancer did not have a significant impact on OS in our
analysis. ECOG PS, a significant clinical factor for OS in
previous studies, was not correlated with survival
[5,21,22]. This was somewhat expected, because there
were no patients with a PS greater than 2 in this study.
Likewise, age, gender, number and location of initial sites
Table 4: Clinical outcomes
Values 95% CI
Median TTF Gem (mo) 11.50 9 – 14.3
Median OS (mo) 26.90 18 – 32
OS 2 yr (%) 56.40 NA
N° of chemo lines
Median 1 (1 – 6) NA
TTF Gem = Time to Treatment Failure on gemcitabine; OS = Overall 
Survival; OS 2 yr = 2-year Overall Survival; No of chemo lines = 
Number of chemotherapeutic lines; 95% CI = 95% Confidence 
Interval.
Table 5: Response rates and correlation with survival according to CT scans and CA 19-9.
Responses (%) Median OS responders Median OS
Non-responders
p value
CT scans 5 (25%) 24 mo 18.8 mo 0.66
CA 19-9 12 (63%) 20.5 mo 26.9 mo 0.45
CT scans = Computerized Tomography scans; Median OS = Median Overall Survival; mo = months. CT scan responses are based on modified 
WHO criteria. CA 19-9 responses were determined by a 50% drop in the baseline CA19-9 value. p value = level of significance.Journal of Hematology & Oncology 2009, 2:13 http://www.jhoonline.org/content/2/1/13
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of metastasis, and pathologic grade did not correlate with
OS. The presence of liver metastasis is also considered a
poor prognostic factor. The fact that only 3 patients (15%)
had liver metastasis at presentation could have contrib-
uted to the relative prolonged survival outcomes of our
study sample.
The only two factors that significantly influenced OS were
total bilirubin and the serum log CA19-9 at baseline in
our study. Elevated serum bilirubin had a negative impact
on OS, with a HR = 1.31 (p = 0.021). Elevated total
bilirubin probably reflects the severity of initial biliary
obstruction, incomplete drainage from biliary decompres-
sion procedures, hepatic dysfunction due to prolonged
cholestasis or the presence of liver metastasis. Cholestasis
due to tumor biliary obstruction only partially explains
the detrimental contribution of serum bilirubin on OS, as
3 of the 5 patients with elevated bilirubin had a successful
biliary decompression procedure. Since only 5 patients
had elevated bilirubin levels, the association of bilirubin
levels and overall survival should be interpreted with cau-
tion. CA19-9 levels correlated with OS, although in a log-
arithmic rather than in a linear fashion. The decrease in
CA19-9 values after gemcitabine did not correlate with the
length of OS in our study. Since the patients included in
this analysis were selected for at least one year survival
after initiation of gemcitabine therapy, and the group as a
whole had a relatively high proportion of CA19-9
responders (63%), it is perhaps not surprising that there
was not a detectable effect of CA19-9 response on dura-
tion of survival.
Previously,  Heinemann et al described a correlation of
decreasing levels of CA19-9 and clinical response in
patients treated with gemcitabine and cisplatin [23].
However, they did not describe the correlation of CA19-9
response to survival and did not perform any statistical
analysis. Saad et al demonstrated a significant correlation
between the pretreatment serum CA19-9 levels, CA 19-9
response and OS in 28 patients with advanced pancreatic
cancer treated with gemcitabine. In their multivariate
analysis, they found that both baseline and CA19-9
response correlated to OS (p = .0005 and .0497, respec-
tively) [24]. Similarly, in a series of 43 patients, Halm et al
showed a significant higher OS for patients with a greater
than 20% decrease in CA19-9 values from baseline after
treatment with gemcitabine [25]. In this analysis, CA19-9
responses were the strongest predictor of OS. Ueno et al
have performed a retrospective study of 103 patients with
metastatic disease treated with systemic chemotherapy. In
their report, serum C-reactive protein ≥ 5 mg/dL, PS of 2
or 3 and CA19-9 above 10,000 U/mL correlated signifi-
cantly to shorter OS after a multivariate analysis [22].
These results suggest prognostic and predictive value of
both baseline and changes in post treatment CA19-9 for
OS in patients with metastatic pancreatic cancer.
Because only six patients had a surgical resection, we
could not address the impact of margins and involvement
of lymph nodes on length of survival. Six patients with 1
to 7 positive nodes had an OS of 13.1 to 25.0 months after
recurrence. In addition, 4 patients with positive margins
showed an OS of 17.7 to 25 months after recurrence.
Thus, occasionally patients with positive lymph nodes or
margins at the time of resection can have survival dura-
tions up to two years. Although the difference in OS
between patients with well and moderately differentiated
tumors compared to those with poorly differentiated
tumors did not reach statistical significance, there were
only 12 patients with available information on histologi-
cal grade, which might limit the power to detect smaller
differences. Among resected cases, only one tumor meas-
ured less than 3 cm, all patients had perineural extension,
83% had positive lymph nodes and 66% had positive sur-
gical margins, all features of aggressive behavior and poor
prognosis [26-29]. Based on this study, no histopatholog-
ical characteristics correlated with OS.
Currently, there is no universally accepted standard sec-
ond-line chemotherapy after gemcitabine failure for met-
astatic pancreatic cancer although a 5-FU (or
capecitabine) based regimen would be most commonly
used. We demonstrated that in a selected subgroup of
patients, median TTF on gemcitabine and OS were 11.5
and 26.9 months, respectively. Therefore, median inter-
vals greater than 1 year between gemcitabine withdrawal
and death can be expected in these cases. In this study, 10
patients (50%) received at least a second-line treatment
and the median number of chemotherapeutic regimens or
experimental therapy in patients receiving more than one
regimen was 3. These data suggest that a significant
number of patients who survive more than 1 year with
metastatic pancreatic cancer will still be candidates for fur-
ther therapies after gemcitabine failure. Future trials of
second-line therapies for this selected population seem to
be warranted.
Although gemcitabine is a well-tolerated chemotherapeu-
tic agent with a favorable toxicity profile, long-term use of
gemcitabine is associated with potential development of
HUS and other uncommon toxicities, as shown in this
and our previous study [30]. This highlights the impor-
tance of continued monitoring for HUS and other side
effects for patients undergoing prolonged treatment with
gemcitabine.
Conclusion
A subgroup of patients with metastatic pancreatic cancer
treated with gemcitabine has a significantly better out-
come than most patients. Besides CA19-9 and total
bilirubin, no clinical or pathologic features correlated
with duration of survival in these highly selected patients.
Continued investigation of key molecular markers thatJournal of Hematology & Oncology 2009, 2:13 http://www.jhoonline.org/content/2/1/13
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might be capable of predicting prognosis and treatment
response in pancreatic cancer patients is needed in future
clinical trials. Given the relatively long median survival of
this group of patients after disease progression on gemcit-
abine, additional systemic therapies after gemcitabine
failure may improve the clinical outcomes for selected
patients with metastatic pancreatic adenocarcinoma.
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